XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders’ Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Stock Option Activity

The number of shares available under the Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated (the “Plan”), was increased by 250,000 at the Company’s Annual Meeting of Stockholders on June 16, 2023. A summary of stock option activity under the Plan, during the nine months ended September 30, 2023 is presented below:

 

   Options Outstanding 
   Number of Shares   Weighted- Average Exercise Price Per Share 
Outstanding December 31, 2022   1,037,591   $6.46 
Granted   86,000    4.70 
Cancelled or expired   (62,883)   8.17 
Outstanding September 30, 2023   1,060,708   $6.21 
Schedule of Stock-based compensation

Stock-based compensation was as follows for the three and nine months ended September 30, 2023 and 2022:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
General and administrative  $95,189   $160,233   $540,260   $482,609 
Research and development   95,566    140,880    376,415    375,041 
Total stock-based compensation  $190,755   $301,113   $916,675   $857,650